Severe left atrial enlargement due to carfilzomib use in multiple myeloma.
J Oncol Pharm Pract
; 25(8): 2045-2048, 2019 Dec.
Article
in En
| MEDLINE
| ID: mdl-30636528
ABSTRACT
Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly by treating physicians and pharmacists. Special attention is required in patients with pre-existing cardiac conditions, liver function abnormalities and/or advanced age. This is the first report of a severe left atrial enlargement due to carfilzomib use in the setting of multiple myeloma. This condition improved dramatically seven months after cessation of carfilzomib. The authors discuss further various cardiac and vascular abnormalities linked with carfilzomib in the medical literature. Prompt withdrawal of this agent is essential in these cases as it may prevent dismal outcomes.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oligopeptides
/
Heart Atria
/
Multiple Myeloma
Type of study:
Etiology_studies
Limits:
Aged
/
Humans
/
Male
Language:
En
Journal:
J Oncol Pharm Pract
Journal subject:
FARMACIA
Year:
2019
Type:
Article
Affiliation country:
United States